<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028014</url>
  </required_header>
  <id_info>
    <org_study_id>VESI-9E03-UAB</org_study_id>
    <nct_id>NCT01028014</nct_id>
  </id_info>
  <brief_title>Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters</brief_title>
  <official_title>Medication Effects on Periurethral Sensation, Urethral Sphincter Activity and Pressure Flow Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lower urinary tract symptoms such as urinary leakage and overactive bladder affect millions
      of American women. Women may develop these problems because the innervation of the muscles of
      the bladder and urethra are injured. Most research on treating these problems has focused on
      the abnormalities of the bladder muscle, but newer studies have shown abnormalities in the
      innervation and muscle function of the urethra.

      Women with these symptoms may benefit from treatment with medications to improve their
      urethral function. However, to truly understand what types of medications will help women
      with these symptoms, the investigators wish to study how these medications affect innervation
      and muscle function in healthy women who do not have lower urinary tract symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women without urinary incontinence or bladder symptoms (healthy controls)will undergo
      urethral testing prior to randomization to one of 5 medications or placebo. Participants will
      take an oral medication for 2 weeks and then return for repeat testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG</measure>
    <time_frame>2 weeks</time_frame>
    <description>Concentric needle EMG was used to measure urethral sphincter activity at 2-3 sites around the urethral meatus before and after 2 weeks of therapy with one of 6 randomly assigned medications. Two methods of quantitative electromyography were performed on all subjects. (1) Multi-Motor Unit Action Potential (MUP) analysis, which has been shown to be the most sensitive technique in distinguishing neuropathic from control muscles; and (2) interference pattern analysis (IPA) which reflects changes in MUP recruitment from weak effort to maximal contraction.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Urethral Sphincter Activity</condition>
  <arm_group>
    <arm_group_label>Pseudoephedrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pseudoephedrine 120mg extended release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solifenacin 5mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulosin 0.4mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipramine 25mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclobenzaprine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclobenzaprine 10mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine</intervention_name>
    <description>Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks</description>
    <arm_group_label>Pseudoephedrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Tamsulosin 0.4mg by mouth daily for 2 weeks</description>
    <arm_group_label>Tamsulosin</arm_group_label>
    <other_name>Flomax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine</intervention_name>
    <description>Imipramine 25mg daily by mouth for 2 weeks</description>
    <arm_group_label>Imipramine</arm_group_label>
    <other_name>Tofranil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine</intervention_name>
    <description>Cyclobenzaprine 10mg daily by mouth for 2 weeks</description>
    <arm_group_label>Cyclobenzaprine</arm_group_label>
    <other_name>Flexeril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose capsule</intervention_name>
    <description>Lactose capsule 1 by mouth daily for 2 weeks</description>
    <arm_group_label>Lactose capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>Solifenacin 5mg by mouth daily for 2 weeks</description>
    <arm_group_label>Solifenacin</arm_group_label>
    <other_name>VESIcare</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Females only

          -  Ages 19-51 and up including pre-menopausal older women who have had a normal menstrual
             cycle for the prior 3 months

          -  Able to take oral medication for 2 weeks

          -  For women of child bearing potential,willing to use an approved method of birth
             control during the study

        Exclusion Criteria:

          -  Urinary Incontinence or other bladder symptoms

          -  Known neurologic disease that may impair urethral tone or sensation

          -  Currently taking a class of medication that is being tested (alpha-antagonists,
             anticholinergics, sympathomimetics, tricyclic antidepressants, or skeletal muscle
             relaxants)

          -  History of QTc prolongation or cardiac arrhythmia

          -  Pregnant, breastfeeding, or are less than 6 months postpartum

          -  Known hypersensitivity to or other contraindications to taking any of the study
             medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holly E Richter, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham, The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Greer WJ; Gleason J; Szychowski JM; Goode P; Kenton K; Richter HE. Medication Effects on Urethral Current Perception Thresholds and Pressure Flow Parameters. Fem Pelv Med Recons Surg 2011;17:S33.</citation>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <results_first_submitted>June 29, 2011</results_first_submitted>
  <results_first_submitted_qc>August 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2011</results_first_posted>
  <last_update_submitted>June 1, 2012</last_update_submitted>
  <last_update_submitted_qc>June 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Holly Richter, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Imipramine</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Cyclobenzaprine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy women,ages 19-51 and up including pre-menopausal older women who have had a normal menstrual cycle for the prior 3 months.Participants were recruited via local newspaper. The first participant was enrolled 5/27/10. Recruitment ended August 31, 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pseudoephedrine 120mg ER Daily</title>
          <description>120 mg extended release tablet one daily for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Solifenacin 5mg Daily</title>
          <description>5 mg capsule, one daily for 14 days</description>
        </group>
        <group group_id="P3">
          <title>Tamsulosin 0.4mg Daily</title>
          <description>0.4 mg capsule, one daily for 14 days</description>
        </group>
        <group group_id="P4">
          <title>Imipramine 25mg Daily</title>
          <description>25 mg tablet, one daily for 14 days</description>
        </group>
        <group group_id="P5">
          <title>Cyclobenzaprine 10mg Daily</title>
          <description>10 mg tablet, one daily for 14 days</description>
        </group>
        <group group_id="P6">
          <title>Lactose Capsules, One Daily</title>
          <description>sham lactose capsules, one daily for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pseudoephedrine 120mg ER Daily</title>
          <description>120 mg extended release, 1 daily for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Solifenacin 5mg Daily</title>
          <description>5 mg capsule, 1 daily for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Tamsulosin 0.4mg Daily</title>
          <description>0.4 mg capsule, 1 daily for 14 days</description>
        </group>
        <group group_id="B4">
          <title>Imipramine 25mg Daily</title>
          <description>25 mg tablet, 1 daily for 14 days</description>
        </group>
        <group group_id="B5">
          <title>Cyclobenzaprine 10mg Daily</title>
          <description>10 mg tablet, 1 daily for 14 days</description>
        </group>
        <group group_id="B6">
          <title>Lactose Capsules, One Daily</title>
          <description>sham lactose capsules, 1 daily for 14 days</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" lower_limit="24" upper_limit="49"/>
                    <measurement group_id="B2" value="31.6" lower_limit="21" upper_limit="35"/>
                    <measurement group_id="B3" value="35.5" lower_limit="21" upper_limit="49"/>
                    <measurement group_id="B4" value="33.1" lower_limit="21" upper_limit="50"/>
                    <measurement group_id="B5" value="38" lower_limit="24" upper_limit="53"/>
                    <measurement group_id="B6" value="28.7" lower_limit="21" upper_limit="35"/>
                    <measurement group_id="B7" value="34.3" lower_limit="19" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG</title>
        <description>Concentric needle EMG was used to measure urethral sphincter activity at 2-3 sites around the urethral meatus before and after 2 weeks of therapy with one of 6 randomly assigned medications. Two methods of quantitative electromyography were performed on all subjects. (1) Multi-Motor Unit Action Potential (MUP) analysis, which has been shown to be the most sensitive technique in distinguishing neuropathic from control muscles; and (2) interference pattern analysis (IPA) which reflects changes in MUP recruitment from weak effort to maximal contraction.</description>
        <time_frame>2 weeks</time_frame>
        <population>The planned number of participants was per protocol based on power calculation. Actual number may differ based on withdrawal from the study or loss to follow-up.Participants randomized to Pseudoephedrine 120 mg ER,Solifenacin 5 mg, Tamsulosin 0.4mg, Imipramine 25mg, Cyclobenzaprine 10 mg, or a sham Lactose capsule, 1 a day for 14 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Pseudoephedrine 120mg ER Daily</title>
            <description>120 mg extended release, 1 tablet daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin 5mg Daily</title>
            <description>5 mg capsule, 1 capsule daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4mg Daily</title>
            <description>0.4 mg capsule, 1 daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Imipramine 25mg Daily</title>
            <description>25 mg tablet, 1 daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>Cyclobenzaprine 10mg Daily</title>
            <description>10 mg tablet, 1 daily for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Lactose Capsules, One Daily</title>
            <description>sham lactose capsules, 1 daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG</title>
          <description>Concentric needle EMG was used to measure urethral sphincter activity at 2-3 sites around the urethral meatus before and after 2 weeks of therapy with one of 6 randomly assigned medications. Two methods of quantitative electromyography were performed on all subjects. (1) Multi-Motor Unit Action Potential (MUP) analysis, which has been shown to be the most sensitive technique in distinguishing neuropathic from control muscles; and (2) interference pattern analysis (IPA) which reflects changes in MUP recruitment from weak effort to maximal contraction.</description>
          <population>The planned number of participants was per protocol based on power calculation. Actual number may differ based on withdrawal from the study or loss to follow-up.Participants randomized to Pseudoephedrine 120 mg ER,Solifenacin 5 mg, Tamsulosin 0.4mg, Imipramine 25mg, Cyclobenzaprine 10 mg, or a sham Lactose capsule, 1 a day for 14 days.</population>
          <units>microvolts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18" lower_limit="-108" upper_limit="89"/>
                    <measurement group_id="O2" value="10" lower_limit="-56" upper_limit="60"/>
                    <measurement group_id="O3" value="11" lower_limit="-102" upper_limit="52"/>
                    <measurement group_id="O4" value="-15" lower_limit="-157" upper_limit="75"/>
                    <measurement group_id="O5" value="12" lower_limit="-71" upper_limit="104"/>
                    <measurement group_id="O6" value="36" lower_limit="23" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Using difference in EMG amplitude as primary outcome, assuming standard deviation of 6, we had greater than 80% power to detect a 10-microvolt change in urethral muscle activity with sample size of 9 participants per group. Due to non-normality and small sample sizes, non-parametric tests were used and data presented as median (IQR). Kruskal-Wallis p-values are reported to compare median scores across groups. Wilcoxon sign-test p-values are reported to evaluate 2-week change within groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>P values comparing differences across groups, as well as within group changes, were all &gt;0.05.P-values were not adjusted for multiple testing; p&lt;0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference (Pre - Post) in Urethral Sensation (Milliamps) as Measured by Current Perception Threshold Testing.</title>
        <description>Current Perception Threshold testing was used to measure urethral sensation before and after 2 weeks of therapy with one of 6 randomly assigned medications. We performed CPT testing in the urethra using a Neurometer®, which is a constant current stimulator capable of delivering sine wave electrical stimuli at 3 frequencies (2000 Hz, 250 Hz and 5 Hz). At all 3 frequencies, the stimulus intensity was gradually increased until first perceived, and then decreased until no longer perceptible. CPT values were obtained using a semi-automated forced choice paradigm.</description>
        <time_frame>2 weeks</time_frame>
        <population>The planned number of participants was per protocol based on power calculation. Actual number may differ based on withdrawal from the study or loss to follow-up.Participants randomized to Pseudoephedrine 120 mg ER,Solifenacin 5 mg, Tamsulosin 0.4mg, Imipramine 25mg, Cyclobenzaprine 10 mg, or a sham Lactose capsule, 1 a day for 14 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Pseudoephedrine 120mg ER Daily</title>
            <description>120 mg extended release, 1 tablet daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin 5mg Daily</title>
            <description>5 mg capsule, 1 capsule daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4mg Daily</title>
            <description>0.4 mg capsule, 1 daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Imipramine 25mg Daily</title>
            <description>25 mg tablet, 1 daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>Cyclobenzaprine 10mg Daily</title>
            <description>10 mg tablet, 1 daily for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Lactose Capsules, One Daily</title>
            <description>sham lactose capsules, 1 daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Difference (Pre - Post) in Urethral Sensation (Milliamps) as Measured by Current Perception Threshold Testing.</title>
          <description>Current Perception Threshold testing was used to measure urethral sensation before and after 2 weeks of therapy with one of 6 randomly assigned medications. We performed CPT testing in the urethra using a Neurometer®, which is a constant current stimulator capable of delivering sine wave electrical stimuli at 3 frequencies (2000 Hz, 250 Hz and 5 Hz). At all 3 frequencies, the stimulus intensity was gradually increased until first perceived, and then decreased until no longer perceptible. CPT values were obtained using a semi-automated forced choice paradigm.</description>
          <population>The planned number of participants was per protocol based on power calculation. Actual number may differ based on withdrawal from the study or loss to follow-up.Participants randomized to Pseudoephedrine 120 mg ER,Solifenacin 5 mg, Tamsulosin 0.4mg, Imipramine 25mg, Cyclobenzaprine 10 mg, or a sham Lactose capsule, 1 a day for 14 days.</population>
          <units>Milliamps</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.0" upper_limit="0.68"/>
                    <measurement group_id="O2" value="0.06" lower_limit="-0.01" upper_limit="0.34"/>
                    <measurement group_id="O3" value="-0.8" lower_limit="-0.8" upper_limit="0.04"/>
                    <measurement group_id="O4" value="-0.12" lower_limit="-0.4" upper_limit="0.12"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-0.16" upper_limit="0.28"/>
                    <measurement group_id="O6" value="0.03" lower_limit="-0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Using difference in EMG amplitude as primary outcome, assuming standard deviation of 6, we had greater than 80% power to detect a 10-microvolt change in urethral muscle activity with sample size of 9 participants per group. Due to non-normality and small sample sizes, non-parametric tests were used and data presented as median (IQR). Kruskal-Wallis p-values are reported to compare median scores across groups. Wilcoxon sign-test p-values are reported to evaluate 2-week change within groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>P values comparing differences across groups, as well as within group changes, were all &gt;0.05.P-values were not adjusted for multiple testing; p&lt;0.05 was considered statistically significant.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference (Pre - Post) in Maximum Urine Flow Rate (Qmax) (Milliliters Per Second) as Measured by Pressure Flowmetry</title>
        <description>Pressure Flowmetry was used to measure maximum urine flow rate (Qmax)before and after 2 weeks of therapy with one of 6 randomly assigned medications. A 300 cc bladder fill was performed through the catheter, the catheter was removed, and transurethral and transrectal pressure transducers were placed for the pressure flow study. Voiding was performed in the seated position. Information obtained for the database included Qmax, average flow rate, time to Qmax, detrusor pressure at maximum flow rate, voided volume, and a calculated post-void residual.</description>
        <time_frame>2 weeks</time_frame>
        <population>The planned number of participants was per protocol based on power calculation. Actual number may differ based on withdrawal from the study or loss to follow-up.Participants randomized to Pseudoephedrine 120 mg ER,Solifenacin 5 mg, Tamsulosin 0.4mg, Imipramine 25mg, Cyclobenzaprine 10 mg, or a sham Lactose capsule, 1 a day for 14 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Pseudoephedrine 120mg ER Daily</title>
            <description>120 mg extended release, 1 tablet daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin 5mg Daily</title>
            <description>5 mg capsule, 1 capsule daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4mg Daily</title>
            <description>0.4 mg capsule, 1 daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Imipramine 25mg Daily</title>
            <description>25 mg tablet, 1 daily for 14 days</description>
          </group>
          <group group_id="O5">
            <title>Cyclobenzaprine 10mg Daily</title>
            <description>10 mg tablet, 1 daily for 14 days</description>
          </group>
          <group group_id="O6">
            <title>Lactose Capsules, One Daily</title>
            <description>sham lactose capsules, 1 daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Difference (Pre - Post) in Maximum Urine Flow Rate (Qmax) (Milliliters Per Second) as Measured by Pressure Flowmetry</title>
          <description>Pressure Flowmetry was used to measure maximum urine flow rate (Qmax)before and after 2 weeks of therapy with one of 6 randomly assigned medications. A 300 cc bladder fill was performed through the catheter, the catheter was removed, and transurethral and transrectal pressure transducers were placed for the pressure flow study. Voiding was performed in the seated position. Information obtained for the database included Qmax, average flow rate, time to Qmax, detrusor pressure at maximum flow rate, voided volume, and a calculated post-void residual.</description>
          <population>The planned number of participants was per protocol based on power calculation. Actual number may differ based on withdrawal from the study or loss to follow-up.Participants randomized to Pseudoephedrine 120 mg ER,Solifenacin 5 mg, Tamsulosin 0.4mg, Imipramine 25mg, Cyclobenzaprine 10 mg, or a sham Lactose capsule, 1 a day for 14 days.</population>
          <units>milliliters per second</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" lower_limit="-23.8" upper_limit="7.2"/>
                    <measurement group_id="O2" value="5.0" lower_limit="-24.5" upper_limit="21.4"/>
                    <measurement group_id="O3" value="-5.6" lower_limit="-45.3" upper_limit="16.5"/>
                    <measurement group_id="O4" value="-6.6" lower_limit="-55.1" upper_limit="8.7"/>
                    <measurement group_id="O5" value="10.3" lower_limit="-30.1" upper_limit="31.9"/>
                    <measurement group_id="O6" value="10.4" lower_limit="-27.6" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data were collected from 5/27/10, the date of first participant enrolled, until 9/20/10 when the last participant completed the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pseudoephedrine 120mg ER Daily</title>
          <description>120mg extended release, one daily for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Solifenacin 5mg Daily</title>
          <description>5 mg capsule, one daily for 14 days</description>
        </group>
        <group group_id="E3">
          <title>Tamsulosin 0.4mg Daily</title>
          <description>0.4 mg capsule, one daily for 14 days</description>
        </group>
        <group group_id="E4">
          <title>Imipramine 25mg Daily</title>
          <description>25 mg tablet, one daily for 14 days</description>
        </group>
        <group group_id="E5">
          <title>Cyclobenzaprine 10mg Daily</title>
          <description>10mg tablet, one daily for 14 days</description>
        </group>
        <group group_id="E6">
          <title>Lactose Capsules, One Daily</title>
          <description>sham lactose capsules, one daily for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <description>Dry mouth resolved after the first two days of study medication.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Subject had mild nausea at bedtime after taking study medication. Instructed to take medication iwth food at dinner time and the problem was resolved.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <description>Reported migraine like headaches over the weekend. Headaches stopped two days later. No further problems with headaches.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Voiding discomfort</sub_title>
                <description>Discomfort with voiding; improved with Azo-Standard.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Yeast Infection</sub_title>
                <description>Problem resolved after she took Diflucan that she had at home.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Jerod Greer</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-7874</phone>
      <email>wjgreer@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

